OCC Orthocell spikes 7% after clearing huge US hurdle for its nerve repair product The stock’s bull run over the last two months has seen its share price more than double as investors eye the lucrative $1.6B nerve repair market in the US. Sean Boss 12 hours ago ASX News Healthcare Biotechnology
1AI Monash tests show strong cardioprotective qualities for Algorae drug candidate Algorae Pharmaceutical Ltd has completed preclinical tests on its drug candidate for heart disease, AI-168 Caroline Smith 4 days ago ASX News Healthcare Biotechnology
CHM Chimeric clocks $4.17M R&D tax rebate from Canberra Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities. Jonathon Davidson 5 days ago ASX News Healthcare Steel Biotechnology Basic Materials
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. Jonathon Davidson 25 Nov 2024 03:00 (AEDT) ASX News Healthcare Biotechnology
PYC Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore Caroline Smith 22 Nov 2024 13:18 (AEDT) ASX News Healthcare Biotechnology
RAC Race identifies 39 new molecules with potential to inhibit cancer-associated protein Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne Caroline Smith 21 Nov 2024 11:39 (AEDT) ASX News Healthcare Biotechnology
RAD Radiopharm extends radioimmunotherapy trial to 5 more cancer types Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types Caroline Smith 19 Nov 2024 14:55 (AEDT) ASX News Healthcare Biotechnology
RAD Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win Radiopharm Theranostics (ASX:RAD) has seen the safety profile of its pancreatic cancer imaging drug RAD 301 boosted by a published study. Jonathon Davidson 18 Nov 2024 11:32 (AEDT) ASX News Healthcare Biotechnology
ACW Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial Actinogen Medical Ltd has received a $9M R&D rebate from the Australian Taxation Office which will fund its activities through to mid-2026 Caroline Smith 12 Nov 2024 13:41 (AEDT) ASX News Healthcare Biotechnology
IMU Imugene kicks off Australian trial for blood cancer treatment Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test CAR T cell therapy azer-cel Caroline Smith 08 Nov 2024 13:33 (AEDT) ASX News Healthcare Biotechnology
PYC PYC Therapeutics moves into final stage of child blindness study PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort. Jonathon Davidson 05 Nov 2024 09:52 (AEDT) ASX News Healthcare Biotechnology
DXB Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study Dimerix Ltd is set to partner with a key research network at the University of Michigan which should boost recruitment Caroline Smith 01 Nov 2024 16:19 (AEDT) ASX News Healthcare Biotechnology
PYC Biotech stock PYC doses first patient in rare blindness-causing disease trial PYC has dosed its first patient in a clinical trial seeking to ameliorate symptoms of Autosomal Dominant Optic Atrophy (ADAO). Jonathon Davidson 01 Nov 2024 12:08 (AEDT) ASX News Healthcare Biotechnology
